Balyasny Asset Management L.P. Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Balyasny Asset Management L.P. cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 56.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 165,973 shares of the biotechnology company's stock after selling 218,359 shares during the quarter. Balyasny Asset Management L.P. owned approximately 0.17% of Sarepta Therapeutics worth $20,181,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after buying an additional 117,904 shares in the last quarter. Capital International Investors boosted its stake in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 0.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock valued at $237,901,000 after purchasing an additional 10,343 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after purchasing an additional 9,999 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at about $126,315,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of recent analyst reports. Morgan Stanley cut their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer decreased their price target on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler cut their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Guggenheim cut their price objective on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.22.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Trading Up 1.3%

Shares of NASDAQ:SRPT traded up $0.48 during trading on Tuesday, hitting $36.85. The company had a trading volume of 2,460,191 shares, compared to its average volume of 1,652,021. The company has a fifty day simple moving average of $65.42 and a two-hundred day simple moving average of $99.77. Sarepta Therapeutics, Inc. has a one year low of $34.95 and a one year high of $173.25. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of 29.48 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same period in the prior year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue was up 80.2% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.